Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05632055

miRNA (microRNA) and FGF21 (Fibroblast Growth Factor-21) Profile in First Trimester and Gestational Diabetes Prediction

The goal of this observational study is to compare miRNA and FGF21 in pregnancy with and without GDM (Gestational Diabetes) The main question it aims to answer that miRNA and FGF21 are different between two groups.

Participants will be retrieved blood sample during first trimester and undergone 100 gm OGTT (oral glucose challenge test) during 24-28 weeks of gestation.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Gestational Diabetes Diabetes Mellitus Diabetes, Gestational Endocrine System Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Pregnancy Complications Urogenital Diseases

Age range

Up to 45 year

Sex eligibility

Female

Study type

Observational

Primary location

Maharaj Nakorn ChiangMai Hospital

Chiang Mai, ChiangMai, 50200, Thailand

About this study

Pregnant women who attended antenatal care at Maharaj Nakorn Chiang Mai hospital during first trimester were recruited.

Participants received routine standard prenatal care except,

  • additional blood test during 11-13 week 6 days (Blood was collected for further analysis)
  • performed 75gm OGTT during 24-28 week

Baseline data and pregnancy outcome were reviewed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • singleton pregnant women who attend at our clinic in first trimester

Exclusion criteria

  • known underlying disease such as chronic hypertension, pregestational diabetes, SLE
  • normal structural fetal anatomical screening
  • incomplete obstetric data

Treatment and study plan

Blood Draw

Other

Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management

Primary outcomes

  1. miRNA profile

    Time frame: within 1 month after blood drawn

    miRNA profile in first trimester of pregnancy and efficacy for GDM prediction

Secondary outcomes

  1. FGF21 profile

    Time frame: 6 months after blood drawn

    FGF21 profile in first trimester of pregnancy and efficacy for GDM prediction

Sponsors and collaborators

Lead sponsor

Chiang Mai University

Other

Registry information

Official study title

miRNA and FGF21 Profile in First Trimester and Efficacy of Gestational Diabetes Prediction and Pregnancy Outcomes

Important dates

Study start
2000
Primary completion
2022
Study completion
2026
First posted
Nov 30, 2022
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.